Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 1/20 | 0.35 |
| ▸ | MASP2 | O00187 | 1/20 | 0.34 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.33 |
| ▸ | ESR1 | P03372 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.31 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14294458 | 0.81 | PARP1 (0.39) | CYP2A6MASP2ABCG2PDE10A | |
| SCHEMBL25054255 | 0.77 | CYP2A6 (0.55) | CYP2A6MASP2ABCG2PDE10A | |
| SCHEMBL6405742 | 0.77 | KRAS (0.39) | CYP2A6MASP2ABCG2PDE10A | |
| SCHEMBL19184943 | 0.75 | ABCB1 (0.34) | ESR1 | |
| SCHEMBL11955041 | 0.74 | CYP2A6 (0.59) | CYP2A6ESR1PDE10A | |
| SCHEMBL14268948 | 0.74 | ABCG2 (0.34) | ABCG2 | |
| SCHEMBL21858490 | 0.72 | GABRP (0.44) | MASP2 | |
| SCHEMBL23814996 | 0.72 | ABCG2 (0.32) | ABCG2ALOX5 | |
| SCHEMBL19184747 | 0.71 | PIK3CD (0.30) | — | |
| SCHEMBL6400583 | 0.71 | MASP2 (0.37) | CYP2A6MASP2ABCG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230277534-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2023-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230277534-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, PRKACA, MAP3K13 | CYP2A6 4592/4885MASP2 3427/4885ABCG2 1578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.